This trial evaluated the combination of Cabometyx with against Cabometyx alone in individuals with advanced or metastatic clear cell or non-clear cell renal cell carcinoma (RCC) who had previously shown progression on immune checkpoint inhibitor therapy.

Source: https://seekingalpha.com/article/4607873-exelixis-thriving-investment-opportunity-in-the-evolving-world-of-oncology?source=feed_all_articles

This trial evaluated the combination of Cabometyx with against Cabometyx alone in individuals with advanced or metastatic clear cell or non-clear cell renal cell carcinoma (RCC) who had previously shown progression on immune checkpoint inhibitor therapy.

Source: https://seekingalpha.com/article/4607873-exelixis-thriving-investment-opportunity-in-the-evolving-world-of-oncology?source=feed_all_articles